IGEA Medical Cliniporator® VITAE - Adaptive ...
The Cliniporator® VITAE is the most advanced reversible electroporation technology available from IGEA, enabling professionals to percutaneously access deep-seated lesions – skeletal or visceral. The unit delivers electrical pulses through needle electrodes that can be freely positioned up to 3cm apart to suit the volume, shape and localisation of the target lesion. It also features an R-wave detector to ensure the electrical pulses are delivered during the refractory period of the heart.
The Cliniporator® VITAE facilitates a non-thermal, minimally invasive approach that preserves the surrounding nerves and vessels, while promoting pain relief and quality of life for the patient. A wide range of compatible electrodes are available to customise treatment on a case-by-case basis.
Electrochemotherapy
Using reversible electroporation, electrochemotherapy either intravenously or intratumourally administers a low dose of a chemotherapy drug into the tumour tissue, causing selective cell death by apoptosis due to mitotic division. The Cliniporator® VITAE applies electrical pulses to the tumour via needle electrodes, which facilitates treatment of various superficial and deep-seated sites.
The process is precise to ensure only tumour cells are affected, with tumour nodules disappearing in 30-60 days. Surrounding tissues are further protected as electrochemotherapy delivers non-thermal ablation, which ensures the temperature of the tissue remains the same and adjacent areas are left healthy and undamaged.
Electrosclerotherapy
Similar to electrochemotherapy, electrosclerotherapy is also a non-thermal ablation technique that administers chemotherapy drug bleomycin into the tumour tissue. The Cliniporator® VITAE generates electrical pulses and administers them using special needle electrodes that optimise placement precision and protect the surrounding tissues. Electrosclerotherapy is indicated for treating superficial and deep-seated vascular malformations and is applied intralesionally. Its sclerosing and cytostatic effect significantly reduces vascular malformation volume.
To contact Getz Healthcare about IGEA Medical Cliniporator® VITAE - Adaptive Electroporation Technology use Get a quote.
The Cliniporator® VITAE is the most advanced reversible electroporation technology available from IGEA, enabling professionals to percutaneously access deep-seated lesions – skeletal or visceral. The unit delivers electrical pulses through needle electrodes that can be freely positioned up to 3cm apart to suit the volume, shape and localisation of the target lesion. It also features an R-wave detector to ensure the electrical pulses are delivered during the refractory period of the heart.
The Cliniporator® VITAE facilitates a non-thermal, minimally invasive approach that preserves the surrounding nerves and vessels, while promoting pain relief and quality of life for the patient. A wide range of compatible electrodes are available to customise treatment on a case-by-case basis.
Electrochemotherapy
Using reversible electroporation, electrochemotherapy either intravenously or intratumourally administers a low dose of a chemotherapy drug into the tumour tissue, causing selective cell death by apoptosis due to mitotic division. The Cliniporator® VITAE applies electrical pulses to the tumour via needle electrodes, which facilitates treatment of various superficial and deep-seated sites.
The process is precise to ensure only tumour cells are affected, with tumour nodules disappearing in 30-60 days. Surrounding tissues are further protected as electrochemotherapy delivers non-thermal ablation, which ensures the temperature of the tissue remains the same and adjacent areas are left healthy and undamaged.
Electrosclerotherapy
Similar to electrochemotherapy, electrosclerotherapy is also a non-thermal ablation technique that administers chemotherapy drug bleomycin into the tumour tissue. The Cliniporator® VITAE generates electrical pulses and administers them using special needle electrodes that optimise placement precision and protect the surrounding tissues. Electrosclerotherapy is indicated for treating superficial and deep-seated vascular malformations and is applied intralesionally. Its sclerosing and cytostatic effect significantly reduces vascular malformation volume.
To contact Getz Healthcare about IGEA Medical Cliniporator® VITAE - Adaptive Electroporation Technology use Get a quote.
Thanks for your help!
Sorry! Unable to submit your request at this time. Please try again later.
Report this product